HOME
CAREER NETWORK
NEWS
HOTBEDS
EVENT CENTER
CAREER FAIRS
COMPANY PROFILES
RESEARCH STORE
ABOUT US
NEWSLETTERS Free Newsletters Archive My Subscriptions NEWS News by Subject News by Disease News by Date PLoS Search News Post Your News JoVE CAREER NETWORK Job Seeker Login Most Recent Jobs Browse Biotech Jobs Search Jobs Post Resume Career Fairs Career Resources For Employers HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia DIVERSITY INVESTOR Market Summary News IPOs PROFILES Company Profiles START UPS Companies Events INTELLIGENCE Research Store INDUSTRY EVENTS Biotech Events Post an Event RESOURCES Real Estate Business Opportunities
by Ma. Reina D. Improgo, Christopher W. Johnson, Andrew R. Tapper, Paul D. Gardner
Frontline treatment of small cell lung carcinoma (SCLC) relies heavily on chemotherapeutic agents and radiation therapy. Though SCLC patients respond well to initial cycles of chemotherapy, they eventually develop resistance. Identification of novel therapies against SCLC is therefore imperative.
We have designed a bioluminescence-based cell viability assay for high-throughput screening of anti-SCLC agents. The assay was first validated via standard pharmacological agents and RNA interference using two human SCLC cell lines. We then utilized the assay in a high-throughput screen using the LOPAC1280 compound library. The screening identified several drugs that target classic cancer signaling pathways as well as neuroendocrine markers in SCLC. In particular, perturbation of dopaminergic and serotonergic signaling inhibits SCLC cell viability.
The convergence of our pharmacological data with key SCLC pathway components reiterates the importance of neurotransmitter signaling in SCLC etiology and points to possible leads for drug development.